Literature DB >> 19644145

Cautions and caveats to the treatment of acquired hemophilia A.

Angela Huth-Kühne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19644145      PMCID： PMC2719045          DOI： 10.3324/haematol.2009.011841

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

Review 1.  Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.

Authors:  Julio Delgado; Victor Jimenez-Yuste; Fernando Hernandez-Navarro; Ana Villar
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

2.  Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII.

Authors:  B Guillet; C Pinganaud; V Proulle; M Dreyfus; T Lambert
Journal:  Thromb Haemost       Date:  2002-10       Impact factor: 5.249

Review 3.  Rituximab for the treatment of acquired antibodies to factor VIII.

Authors:  Wolfgang R Sperr; Klaus Lechner; Ingrid Pabinger
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

Review 4.  Autoimmune hemophilia at rescue.

Authors:  Pier Mannuccio Mannucci; Flora Peyvandi
Journal:  Haematologica       Date:  2009-04       Impact factor: 9.941

5.  Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

Authors:  Peter W Collins; Sybil Hirsch; Trevor P Baglin; Gerard Dolan; John Hanley; Michael Makris; David M Keeling; Ri Liesner; Simon A Brown; Charles R M Hay
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

6.  A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.

Authors:  E Santagostino; M E Mancuso; A Rocino; G Mancuso; F Scaraggi; P M Mannucci
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

7.  Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial.

Authors:  Khan Kavakli; Mike Makris; Bulent Zulfikar; Elizabeth Erhardtsen; Zvi S Abrams; Gili Kenet
Journal:  Thromb Haemost       Date:  2006-04       Impact factor: 5.249

Review 8.  The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.

Authors:  Charles R M Hay; S Brown; P W Collins; D M Keeling; R Liesner
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

9.  A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies.

Authors:  D Green; A W Rademaker; E Briët
Journal:  Thromb Haemost       Date:  1993-11-15       Impact factor: 5.249

10.  International recommendations on the diagnosis and treatment of patients with acquired hemophilia A.

Authors:  Angela Huth-Kühne; Francesco Baudo; Peter Collins; Jørgen Ingerslev; Craig M Kessler; Hervé Lévesque; Maria Eva Mingot Castellano; Midori Shima; Jean St-Louis
Journal:  Haematologica       Date:  2009-04       Impact factor: 9.941
  10 in total
  1 in total

1.  Successful eradication of acquired factor-VIII-inhibitor using single low-dose rituximab.

Authors:  Martin Wermke; Malte von Bonin; Siegmund Gehrisch; Gabriele Siegert; Gerhard Ehninger; Uwe Platzbecker
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.